EUVIMEDExplore EUVIMED
Open access · CC BY-NC-ND 4.0

Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report

Alex Ng iD, David I Harriman iD, Alan C Farney iD, Giuseppe Orlando iD, Colleen Jay iD, Amber Reeves-Daniel, Robert J Stratta iD

Clinical Transplantation · 2026-06 · 40 (6)

DOI: 10.1111/ctr.70587 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2026-06-12. Written by Alex Ng and 6 co-authors. Institution: Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Major MEDLINE topics: Alemtuzumab, Kidney Transplantation, Graft Survival, Graft Rejection. 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliographic detailsCiteRelated studies

Abstract (original language)

Introduction

The effects of induction therapy with the anti‐CD52 monoclonal antibody alemtuzumab on age‐specific outcomes following kidney transplantation (KT) remain inadequately studied. This study aimed to analyze the comparative safety and efficacy of single‐dose alemtuzumab induction in deceased donor (DD) KT recipients according to different recipient age groups.

Methods

Single‐center retrospective nonrandomized cohort review of DDKT recipients stratified by age (30–49/50–69/70 years). All patients received a single 30‐mg intra‐operative dose of alemtuzumab. Standardized management algorithms were used. All patients received triple maintenance immunosuppression with tacrolimus/mycophenolate/steroids.

Results

From September 2012 to December 2018, 723 DDKTs were performed with alemtuzumab induction. Donor age (33.1 ± 15.7 vs. 47.3 ± 16.0 vs. 53.3 ± 13.4 years; p < 0.001) and kidney donor profile index (KDPI, 46.5 ± 25.1 vs. 65.5 ± 23.8 vs. 74.4 ± 20.5%; p < 0.001) increased with increasing recipient age groups. Overall patient ( p < 0.001) and graft ( p < 0.001) but not death‐censored graft survival ( p = 0.6) rates decreased with increasing recipient age strata. Rates of delayed graft function, biopsy‐proven acute rejection, and infectious complications at 1‐year post‐transplant were comparable amongst groups.

Conclusion

In DDKT recipients, alemtuzumab induction does not appear to confer excess risk of graft failure, acute rejection, or short‐term infectious complications in older patients relative to younger counterparts in the setting of triple maintenance immunosuppression.

Subjects

MeSH terms (MEDLINE)

AlemtuzumabKidney TransplantationGraft SurvivalGraft RejectionTissue DonorsKidney Failure, ChronicPostoperative ComplicationsHumansFemaleMiddle AgedMaleRetrospective StudiesAdultFollow-Up StudiesPrognosisAgedKidney Function TestsRisk FactorsAge FactorsGlomerular Filtration RateImmunosuppressive AgentsSurvival Rate

Author keywords

alemtuzumabdeceased donor kidney transplantelderly recipientsgraft survivalkidney transplantationpatient survivalseptuagenarians

Substances

AlemtuzumabImmunosuppressive Agents

Authors and institutions

  • Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Surgery, Section of Transplantation, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Internal Medicine, Section of Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

ORCID profiles: Alex Ng, David I Harriman, Alan C Farney, Giuseppe Orlando, Colleen Jay, Robert J Stratta

Cite

APA

Ng, A., Harriman, D. I., Farney, A. C., Orlando, G., Jay, C., Reeves-Daniel, A., & Stratta, R. J. (2026). Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report. Clinical Transplantation, 40(6). https://doi.org/10.1111/ctr.70587

Vancouver

Ng A, Harriman DI, Farney AC, Orlando G, Jay C, Reeves-Daniel A, et al. Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report. Clinical Transplantation. 2026;40(6). doi:10.1111/ctr.70587

BibTeX
@article{Ng2026,
  author = {Ng, Alex and Harriman, David I and Farney, Alan C and Orlando, Giuseppe and Jay, Colleen and Reeves-Daniel, Amber and Stratta, Robert J},
  title = {Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report},
  journal = {Clinical Transplantation},
  year = {2026},
  volume = {40},
  number = {6},
  doi = {10.1111/ctr.70587}
}
Start for free →